Clinical Research Directory
Browse clinical research sites, groups, and studies.
IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy
Sponsor: Institut Paoli-Calmettes
Summary
Immunotherapy has helped improve the prognosis of metastatic lung cancer. However, only about 40% of patients respond to conventional immunotherapy with anti-PD(L)-1 agents. This research aims to identify biomarkers of response to immunotherapy at the tumor level and to characterize new therapeutic targets
Official title: IMMUNO-LUNG: Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy - IMMUNOLUNG-IPC 2021-069
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2026-02-12
Completion Date
2033-05-12
Last Updated
2026-05-27
Healthy Volunteers
No
Conditions
Interventions
prospective collection of blood and tumor samples
The procedure under study is based on the collection of tissue and blood samples at two time points during the patient's management. The patient will undergo a first sampling at the time of inclusion in the study, followed by a second sampling performed at the time of disease progression. Two types of samples will be collected: blood samples and tumor samples. The protocol-mandated tumor sampling at progression will be performed in the following two situations: 1. If, as part of routine clinical care, a biopsy is planned, an additional tumor sample for the study will be collected. 2. If the patient has consented to undergoing a protocol-specific tumor biopsy at the time of progression
Locations (1)
Rochigneux
Marseille, Institut Paoli Calmettes, France